AIM ImmunoTech — Valuation, Funding & Investors

We're still building this profile — here is what Pulse has covered.

Recent changes

Jun 18, 2026Jun 18, 2026AIM ImmunoTech Files S-1 as Biotech Joins the Reopening IPO Pipeline Pulse story

Latest Pulse

Jun 18, 2026AIM ImmunoTech Files S-1 as Biotech Joins the Reopening IPO PipelineAIM ImmunoTech filed an S-1 with the SEC, adding a clinical-stage biotech name to a public-market pipeline that has been widening past tech into energy and life sciences. Biotech listings have been among the slowest to thaw, so fresh filings are a useful read on whether risk appetite is returning to the sector.→

Coverage Timeline

newest first

Jun 18, 2026IPOAIM ImmunoTech Files S-1 as Biotech Joins the Reopening IPO PipelineS-1 filed→

All Coverage

IPO· Jun 18, 2026

AIM ImmunoTech Files S-1 as Biotech Joins the Reopening IPO Pipeline

IPOS-1 filed

AIM ImmunoTech Files S-1 as Biotech Joins the Reopening IPO Pipeline

AIM ImmunoTech filed an S-1 with the SEC, adding a clinical-stage biotech name to a public-market pipeline that has been widening past tech into energy and life sciences. Biotech listings have been among the slowest to thaw, so fresh filings are a useful read on whether risk appetite is returning to the sector.

Jun 18, 2026

Related Companies

Same sector

Attovia Therapeutics Apnimed Braveheart Bio Latigo Biotherapeutics Scribe Therapeutics